Braak neurofibrillary tangle staging prediction from in vivo MRI metrics
Abstract
Alzheimer's disease diagnosis requires postmortem visualization of amyloid and tau deposits. As brain atrophy can provide assessment of consequent neurodegeneration, our objective was to predict postmortem neurofibrillary tangles (NFT) from in vivo MRI measurements.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1016/j.dadm.2019.07.001
Entities
People
- Caroline Dallaire‐théroux
- Iman Beheshti
- Louis Dieumegarde
- National Alzheimer's Coordinating Center
- Olivier Potvin
- Simon Duchesne
- Stephan Saikali
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Centre hospitalier universitaire de Québec
- Chiron Corporation
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Laboratoires Servier
- Laval University
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense